Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.12.

AUTL has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, July 21st. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair reiterated an "outperform" rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Autolus Therapeutics in a report on Saturday, September 27th.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. Bank of America Corp DE raised its holdings in shares of Autolus Therapeutics by 2,891.7% during the second quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock valued at $2,223,000 after acquiring an additional 942,540 shares during the period. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company's stock valued at $27,360,000 after acquiring an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd raised its holdings in shares of Autolus Therapeutics by 10.5% during the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock valued at $21,660,000 after acquiring an additional 900,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after acquiring an additional 11,289 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $1.61 on Friday. The company has a 50 day moving average of $1.74 and a 200-day moving average of $1.78. The firm has a market cap of $428.49 million, a P/E ratio of -1.92 and a beta of 1.84. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. Equities research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.